SEHK:6855
SEHK:6855Biotechs

Ascentage Pharma (SEHK:6855) Is Up 6.9% After FDA Clears IND For First BTK PROTAC Degrader

Ascentage Pharma Group International recently reported that the US FDA has cleared its IND application for APG-3288, a next-generation BTK-targeted PROTAC degrader, allowing the company to begin clinical trials in patients with relapsed or refractory B-cell malignancies. This step not only extends Ascentage Pharma's efforts in targeted protein degradation but also responds to the medical need created by resistance to existing BTK inhibitors. We will now examine how FDA clearance for...
SEHK:1277
SEHK:1277Oil and Gas

Kinetic Development Group (SEHK:1277) Is Up 17.2% After Securing Long-Term Sierra Leone Rutile Rights – Has The Bull Case Changed?

In December 2025, the board of Kinetic Development Group announced that its Sierra Leone subsidiary Metal Mining had signed cooperation agreements with Minenet to develop and operate a rutile project in Rotifunk, securing exclusive rights to explore, mine, process, and sell heavy sand minerals within a designated 50 square kilometre area until 2049. This long-term project, involving about US$18,000,000 of initial investment, plans up to five production lines and could materially expand...
SEHK:1898
SEHK:1898Oil and Gas

3 Asian Dividend Stocks Yielding Up To 4.8%

As Asian markets navigate a landscape marked by mixed economic signals and cautious optimism, investors are increasingly turning their attention to dividend stocks as a reliable income source. In this context, identifying stocks with strong fundamentals and consistent dividend yields can provide stability amidst market fluctuations.
SEHK:581
SEHK:581Metals and Mining

Asian Penny Stocks To Watch In January 2026

As we enter January 2026, the Asian markets are capturing global attention with their mixed performance amid changing economic conditions. Penny stocks, a term that may seem outdated but remains significant, often refer to smaller or newer companies offering growth potential at lower price points. When these stocks are backed by strong financials and solid fundamentals, they can present compelling opportunities for investors seeking value and growth in under-the-radar companies.
SEHK:9992
SEHK:9992Specialty Retail

Is Morgan Stanley Reframing Pop Mart (SEHK:9992) as a Global IP Platform Rather Than a Toy Seller?

Morgan Stanley recently released a research report on Pop Mart International Group, arguing that investors have misread a slowdown in North American sales as weakness rather than a shift from online to offline channels and broader IP diversification. The report frames Pop Mart as an emerging global IP platform whose overall growth potential may be underappreciated when attention centers too narrowly on US sales and the Labubu line. Next, we’ll examine how Morgan Stanley’s focus on Pop Mart’s...
SEHK:2696
SEHK:2696Biotechs

Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After HLX37 Enters Phase 1 Clinical Study

Shanghai Henlius Biotech (SEHK:2696) has dosed the first patient in its phase 1 trial of HLX37, a bispecific antibody that targets PD-L1 and VEGF in advanced or metastatic solid tumours in Mainland China. See our latest analysis for Shanghai Henlius Biotech. The HLX37 trial update comes after a mixed stretch for the stock, with a 1-day share price return of 2.00% and a 7-day share price return of 11.92% but a 90-day share price return of 15.71%. However, the 1-year total shareholder return of...
SEHK:640
SEHK:640Chemicals

Infinity Development Holdings (SEHK:640) EPS Growth Reinforces Bullish Narratives On Profitability

Infinity Development Holdings (SEHK:640) just posted its FY 2025 results with second half revenue of HK$425.8 million and basic EPS of HK$0.233, backed by trailing 12 month revenue of HK$835.2 million and EPS of HK$0.434. The company has seen revenue move from HK$403.8 million in 2H FY 2024 to HK$425.8 million in 2H FY 2025, while half year EPS shifted from HK$0.211 to HK$0.233. The trailing 12 month EPS growth of 21.7% sits alongside net profit margins at 14.6%, compared with 13.6% a year...
SEHK:2269
SEHK:2269Life Sciences

Is WuXi Biologics (SEHK:2269)'s New Procurement Certification a Signal on Supply Chain Resilience?

WuXi Biologics recently achieved ISO 20400 Sustainable Procurement certification, an international standard that embeds sustainability, transparency, and responsibility into its procurement and supplier management practices. This certification highlights how WuXi Biologics has integrated sustainability across its supplier lifecycle, reinforcing supply chain resilience and its broader environmental, social, and governance profile. We will now examine how this new sustainable procurement...
SEHK:700
SEHK:700Interactive Media and Services

Can Tencent (SEHK:700) Turn Its Expanding AI and Fintech Ecosystem Into Sustainable Monetization?

In recent days, Tencent-backed initiatives have been in the spotlight, from China’s digital yuan pilot, where WeBank will pay quarterly interest subject to stricter identity checks, to Tencent-linked ETFs in emerging markets and portfolio companies like Airwallex and AI firm MiniMax expanding globally and listing in Hong Kong. Together, these developments highlight Tencent’s influence across digital finance, emerging markets exposure, and artificial intelligence, underlining how its...
SEHK:1211
SEHK:1211Auto

Is BYD (SEHK:1211) Priced Right After Mixed Returns And EV Competition Headlines

Wondering if BYD's share price still lines up with its underlying worth, or if market sentiment has moved ahead of the fundamentals. BYD last closed at HK$95.30, with returns of a 0.1% decline over 7 days, a 4.0% decline over 30 days, a 3.5% decline year to date, but a 13.6% gain over 1 year, 35.9% over 3 years and 14.4% over 5 years, which hints at shifting risk and return perceptions over different timeframes. Recent coverage around BYD has focused on its role in the electric vehicle and...